---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-012346"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:07:43.972896+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Femasys reports 2025 revenue up 40.8% to $2.3M; net loss $18.6M; cash into Q3 2026

## Summary
- Revenue increased 40.8% to $2,293,313 in 2025 from $1,629,108 in 2024, driven by FemBloc sales.
- Net loss was $18,627,887 ($0.47 per share) vs $18,816,628 ($0.85 per share) in 2024; EPS improved on share count increase.
- Cash and cash equivalents $9.3M as of Dec 31, 2025; expects to fund operations into Q3 2026.
- Initiated patient enrollment in FINALE pivotal trial for FemBloc; received MDSAP certification.
- Completed $12M financing in late 2025; appointed Kenneth D. Eichenbaum to Board.

## SEC filing metadata
- accession: 0001140361-26-012346
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036126012346/0001140361-26-012346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036126012346/ef20069346_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-012346
- JSON: https://secwatch.observer/filing/0001140361-26-012346.json
- Plain text: https://secwatch.observer/filing/0001140361-26-012346.txt

## Key facts
- Earnings Releases
  FEMASYS INC reported year ended December 31, 2025 results: revenue $2,293,313, net income $18,627,887, EPS ($0.47).
  - Period: year ended December 31, 2025
  - Revenue: $2,293,313
  - Net income: $18,627,887
  - EPS: ($0.47)
  - Result: reported results
  source text: critical gaps with innovative, safe, and technologically advanced solutions.” Financial Results for Year Ended December 31, 2025 • Sales increased by $664,205, or 40.8%, to $2,293,313 in 2025 from $1,629,108 in 2024, primarily due to sales of FemBloc. • Research and development expenses decreased by $638,839, or 7.8%, to $7,577,704 in 2025 compared to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339005/000114036126012346/0001140361-26-012346-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.